The DEEP Project has already brought forth its first results and is continuing along the challenging path of a large, multinational clinical trial, which led in the first phase of the project to a new formulation of deferiprone with a better taste suitable for children, as well as valuable data on the safety of deferiprone and on the correct dosage to be administered.
DEEP-2: almost at the final rush
Another step forward has been made toward the enrollment of new patients in the DEEP-2 study, the phase III multicentre, randomised, open label, non-inferiority active-controlled trial aiming at comparing for the first time the efficacy of deferiprone (DFP) vs deferasirox (DFX) in paediatric patients affected by hereditary haemoglobinopaties requiring chronic transfusions and chelation.
After the sad decision to cancel the General Assembly Meeting in Tunis, due to the disorders which have occurred across the country, the 7th DEEP General Assembly (GA) will take place in Padua (Italy) on April 13th -15th, 2016 with the participation of the whole DEEP Consortium as well as of external experts.
The meeting will be focused on a general update of the project's activities, the progresses and achievements of the DEEP project as well as the finalization of the DEEP-2 and DEEP-3 studies, that are of utmost priority. Among others, the possible amendment to the Protocol as well as the financial resources reallocation according to the recruitment performance at any involved centre will be discussed during the meeting.
In the same context of the GA meeting, the DEEP-2 Investigator Meeting and the 4th Open Meeting will take place.
The ApoPharma point of view:
interview to Dr. Michael Spino
We asked Dr. Michale Spino, President of ApoPharma Inc. to describe the major contribution provided by ApoPharma, one of the project beneficiary, in the fulfillment of the project and what contribution could still be provided.
Medical care and transition phase of thalassemia in different countries: the ICET-A experience
During the last Enpr-EMA (European Network of Paediatric Research at the European Medicines Agency) workshop, held in May 2015, adhering networks have been invited to provide a feedback on published guidance documents on the topic of transition from paediatrics to adults clinical care settings within the long-term clinical studies and follow up for chronic diseases.
The Italian Multiregional Thalassemia Registry: centers characteristics, services and patients’ population
Consorzio per Valutazioni Biologiche e Farmacologiche’s research activity in the pharmacological field is much diversified and it is mainly conducted in the context of national and EU level. It is focused on the development and application of innovative methodologies in clinical trials on small populations, the management of interventional, non-interventional, health technology assessment and pharmacoeconomics studies, and disease registries.
DEEP joins Rare Disease Day in making the voice of rare diseases heard!
The 29th February, 2016 marked the ninth international Rare Disease Day coordinated by EURORDIS. The main objective of Rare Disease Day was to raise awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. The campaign targeted primarily the general public and also sought to raise awareness amongst policy makers, public authorities, industry representatives, researchers, health professionals and anyone who has a genuine interest in rare diseases.
It doesn't matter the name of the holiday or celebration as well as the religion, it’s never too late to wish you happy holidays and a nice weekend.
May peace, joy, hope and happiness be yours EVERYDAY!
Greetings from CVBF